Compass Therapeutics Inc

CMPXNASDAQ · USD
1.14USD-0.03 (-3.00%)
215

Compass Therapeutics Inc (CMPX) Covered Calls

As of September 23, 2026, CMPX has 9 covered call opportunities in the coming three months. Return ranges from 45.3 to 335.9% until expiration. Annualized return ranges from 34.1 to 1,011.2%. The nearest expiration is November 20, 2026. Maximum potential profit is $393.

Read more

Running CMPX covered calls helps you generate consistent income from Compass Therapeutics Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Compass Therapeutics Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best CMPX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if CMPX stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling CMPX covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Compass Therapeutics Inc covered call is worth writing.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1.

The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Income-focused investors, long-term CMPX holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling CMPX covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Compass Therapeutics Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile14.29% Subdued
  • Market cap (M$)211
  • 52 weeks high-82.99%
  • 52 weeks low1.74%
  • Analyst recommendationStrong Buy
    1.40
  • Target price$5.50
    685.90% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-04
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.40
  • EPS growth next 5 years-0.43%

As of September 23, 2026

2026-11-20583.00156.410.050.15188.00160.681011.20-4.27+0.2523,6780.10
2027-01-151143.00156.410.050.35188.00160.68514.47-4.27+0.382,6300.30
2026-11-20582.0070.940.100.1593.0079.49500.22-8.55+0.337,4790.05
2027-01-151142.0070.940.150.3098.0083.76268.18-12.82+0.453,2760.15
2028-01-214855.00327.350.100.80393.00335.90252.79-8.55+0.575580.70
2028-01-214854.00241.880.102.45293.00250.43188.47-8.55+1.00892.35
2028-01-214853.00156.410.250.65208.00177.78133.79-21.37+0.606930.40
2029-01-198492.0070.940.151.4098.0083.7636.01-12.82+0.812741.25
2028-01-214851.5028.210.200.8053.0045.3034.09-17.09+0.6920.60

As of September 23, 2026

Sell covered calls with the data behind you

Find the best CMPX covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial